Targeted therapies and checkpoint inhibitors in sarcoma
| العنوان: | Targeted therapies and checkpoint inhibitors in sarcoma |
|---|---|
| المؤلفون: | Pietro Giovanoli, Epameinondas Gousopoulos, Seung Yong Song, Chantal Pauli, Marco Guidi, Mauro Vasella, Gerrit Grieb, Bong-Sung Kim, Gabriele Storti, Nicole Lindenblatt |
| المساهمون: | University of Zurich |
| المصدر: | QJM: An International Journal of Medicine. 115:793-805 |
| بيانات النشر: | Oxford University Press (OUP), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, business.industry, Immune checkpoint inhibitors, MEDLINE, 610 Medicine & health, General Medicine, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 10049 Institute of Pathology and Molecular Pathology, 030220 oncology & carcinogenesis, Cancer research, medicine, Sarcoma, 10266 Clinic for Reconstructive Surgery, business |
| الوصف: | Sarcomas are defined as a group of mesenchymal malignancies with over 100 heterogeneous subtypes. As a rare and difficult to diagnose entity, micrometastasis is already present at the time of diagnosis in many cases. Current treatment practice of sarcomas consists mainly of surgery, (neo)adjuvant chemo- and/or radiotherapy. Although the past decade has shown that particular genetic abnormalities can promote the development of sarcomas, such as translocations, gain-of-function mutations, amplifications or tumor suppressor gene losses, these insights have not led to established alternative treatment strategies so far. Novel therapeutic concepts with immunotherapy at its forefront have experienced some remarkable success in different solid tumors while their impact in sarcoma remains limited. In this review, the most common immunotherapy strategies in sarcomas, such as immune checkpoint inhibitors, targeted therapy and cytokine therapy are concisely discussed. The programmed cell death (PD)-1/PD-1L axis and apoptosis-inducing cytokines, such as TNF-related apoptosis-inducing ligand (TRAIL), have not yielded the same success like in other solid tumors. However, in certain sarcoma subtypes, e.g. liposarcoma or undifferentiated pleomorphic sarcoma, encouraging results in some cases when employing immune checkpoint inhibitors in combination with other treatment options were found. Moreover, newer strategies such as the targeted therapy against the ancient cytokine macrophage migration inhibitory factor (MIF) may represent an interesting approach worth investigation in the future. |
| تدمد: | 1460-2393 1460-2725 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de4fa4e480cc8931fd2102a3523f27f8Test https://doi.org/10.1093/qjmed/hcab014Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....de4fa4e480cc8931fd2102a3523f27f8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14602393 14602725 |
|---|